084110.KQ
Huons Global Co., Ltd.
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 23,650.00
−3.47%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 846.8B | 847.5B | 813.5B | 758.4B | 664.4B |
| Cost of Revenue | 468.3B | 446.3B | 393.0B | 340.6B | 304.2B |
| Gross Profit | 378.5B | 401.1B | 420.4B | 417.8B | 360.1B |
| Operating Expenses | |||||
| R&D Expense | 61.1B | 66.9B | 67.1B | 59.6B | 52.5B |
| SG&A Expense | 187.9B | 170.2B | 181.0B | 235.3B | 219.1B |
| General & Admin Expense | 14.0B | 19.3B | 20.0B | 18.1B | 15.7B |
| Selling & Marketing Expense | 115.9B | 150.9B | 161.1B | 153.9B | 139.3B |
| Other Expenses | 78.6B | 73.3B | 75.3B | 70.7B | 2.5B |
| Total Operating Expenses | 310.4B | 310.4B | 323.4B | 294.9B | 274.2B |
| Cost and Expenses | 778.7B | 756.8B | 716.5B | 635.5B | 578.4B |
| Operating Income (EBIT) | 68.1B | 90.6B | 97.0B | 122.9B | 86.5B |
| Non-Operating | |||||
| Interest Income | 45.3B | 8.2B | 9.4B | 11.4B | 7.7B |
| Interest Expense | 35.3B | 12.5B | 10.5B | 7.6B | 12.8B |
| Net Interest Income | 10.0B | (4.4B) | (1.0B) | 3.8B | (5.0B) |
| Other Non-Op Income/Expense | 10.5B | 15.1B | (6.6B) | (3.3B) | (85.8B) |
| Non-Operating Income (excl Interest) | (27.9B) | (27.7B) | (3.8B) | 7.0B | 73.1B |
| EBT (Pre-Tax Income) | 78.5B | 106.0B | 90.4B | 119.6B | 655.3M |
| Income Tax Expense | 19.0B | 24.1B | 23.2B | 27.0B | 33.7B |
| Bottom Line | |||||
| Net Income | 22.6B | 28.8B | 25.8B | 38.4B | (60.3B) |
| Earnings from Cont. Ops | 59.5B | 81.8B | 67.1B | 92.6B | (33.1B) |
| Earnings from Discont. Ops | — | — | — | — | (378.1M) |
| Bottom Line Net Income | 22.6B | 28.8B | 25.8B | 38.4B | (60.3B) |
| Per Share | |||||
| Basic EPS | ₩1,852 | ₩2,367 | ₩2,116 | ₩3,134 | (₩4,903) |
| Diluted EPS | ₩1,846 | ₩2,360 | ₩2,116 | ₩3,134 | (₩4,903) |
| Revenue Per Share | ₩69,363 | ₩66,939 | ₩66,628 | ₩61,919 | ₩54,062 |
| Shares | |||||
| Basic Shares Outstanding | 12.2M | 12.7M | 12.2M | 12.2M | 12.3M |
| Diluted Shares Outstanding | 12.2M | 12.7M | 12.2M | 12.2M | 12.3M |
| Profitability Metrics | |||||
| EBITDA | 118.4B | 136.2B | 141.1B | 168.5B | 47.0B |
| D&A | 50.4B | 45.4B | 40.3B | 36.0B | 33.6B |
| EBIT | 68.1B | 90.6B | 100.8B | 132.5B | 13.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026